Heidelberg Epignostix Raises €4.3M for Brain Tumor Classifier Development

Heidelberg Epignostix raises €4.3M in Seed Funding

Heidelberg Epignostix (Linkedin), a precision cancer diagnostics startup, has secured €4.3M in seed funding. With a focus on brain tumor classification, they are seeking collaborations with healthcare providers, cancer diagnostic labs, and research institutions to advance their AI-based bioinformatics algorithms.

Funding Amount: €4.3 million

Industry: Software Development

Employee Count: 10001+

CEO: Ryan Roslansky (CEO Linkedin)

What Heidelberg Epignostix needs to buy: Companies specializing in data science, AI expertise, cancer research, and marketing and sales support are ideal partners for Heidelberg Epignostix. Collaborations in these areas will help drive the development of their bioinformatics algorithms, expand their sample pool, and promote their precision cancer diagnostics solutions to a wider audience.